Van de Winkel CEO Genmab
Prof. Jan G.J. van de Winkel is the new Chief Executive Officer at Genmab.
Co-founder Lisa N. Drakeman Ph.D. has retired from her position as CEO and as member of the board of directors of the company.
Van de Winkel is the company’s former President, Research and Development and Chief Scientific Officer. He has over 20 years of experience in the therapeutic antibody field and served as Scientific Director and Vice President of Medarex Europe prior to co-founding Genmab.
